Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2016 - 2022)

Cumberland Pharmaceuticals (CPIX) has disclosed Accumulated Expenses for 12 consecutive years, with $17.6 million as the latest value for Q4 2022.

  • Quarterly Accumulated Expenses rose 102.9% to $17.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $17.6 million through Dec 2022, up 102.9% year-over-year, with the annual reading at $17.6 million for FY2022, 102.9% up from the prior year.
  • Accumulated Expenses hit $17.6 million in Q4 2022 for Cumberland Pharmaceuticals, up from $8.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $17.6 million in Q4 2022 to a low of $8.7 million in Q4 2021.
  • Historically, Accumulated Expenses has averaged $13.1 million across 5 years, with a median of $11.3 million in 2020.
  • Biggest five-year swings in Accumulated Expenses: plummeted 33.67% in 2019 and later surged 102.9% in 2022.
  • Year by year, Accumulated Expenses stood at $16.7 million in 2018, then tumbled by 33.67% to $11.1 million in 2019, then increased by 1.53% to $11.3 million in 2020, then fell by 22.98% to $8.7 million in 2021, then soared by 102.9% to $17.6 million in 2022.
  • Business Quant data shows Accumulated Expenses for CPIX at $17.6 million in Q4 2022, $8.7 million in Q4 2021, and $11.3 million in Q4 2020.